Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aquestive Therapeutics Inc AQST

Healthcare
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on... see more

Recent & Breaking News (NDAQ:AQST)

AQST INVESTOR LAWSUIT DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Against Aquestive Therapeutics, Inc.

PR Newswire March 3, 2021

AQST BREAKING NEWS: ROSEN, A LEADING LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline - AQST

Business Wire March 3, 2021

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)

GlobeNewswire March 3, 2021

AQST INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc.

GlobeNewswire March 2, 2021

AQST Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Aquestive Therapeutics, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm

ACCESSWIRE IA March 2, 2021

Pomerantz Law Firm Announces the Filing of a Class Action against Aquestive Therapeutics, Inc. and Certain Officers - AQST

Canada NewsWire March 1, 2021

Aquestive Therapeutics Reaffirms Near-Term NDA Resubmission for Libervant(TM) (diazepam) Buccal Film Following FDA Feedback

GlobeNewswire February 25, 2021

Aquestive Therapeutics to Announce Fourth Quarter and Year End 2020 Financial Results and Recent Business Highlights on March 9 and Host Conference Call on March 10 at 8:00 a.m. ET

GlobeNewswire February 17, 2021

Aquestive Therapeutics Strengthens Board of Directors with Appointments of Julie Krop, M.D., and Marco Taglietti, M.D., and Announces Resignation of Douglas K. Bratton from Board of Directors

GlobeNewswire February 9, 2021

Aquestive Therapeutics Appoints Mark Lepore, MD, as Chief Medical Officer for Allergy

GlobeNewswire January 28, 2021

Mitsubishi Tanabe Pharma America and Aquestive Therapeutics Announce U.S. Licensing and Supply Deal for Riluzole Oral Film for ALS Treatment

PR Newswire January 21, 2021

Aquestive Therapeutics Provides Business Update

GlobeNewswire January 7, 2021

Aquestive Therapeutics to Present at Two Upcoming Investor Conferences

GlobeNewswire January 4, 2021

Aquestive Therapeutics Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer

GlobeNewswire December 16, 2020

Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

GlobeNewswire November 25, 2020

Aquestive Therapeutics Receives First Milestone Payment from KYNMOBI(TM) Monetization

GlobeNewswire November 23, 2020

Aquestive Therapeutics Completes FDA Type A Meeting on Libervant

GlobeNewswire November 18, 2020

Aquestive Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire November 4, 2020

Aquestive Therapeutics Signs Royalty Monetization Agreement with Marathon Asset Management for up to $125 Million

GlobeNewswire November 3, 2020

Aquestive Therapeutics to Announce Third Quarter Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET

GlobeNewswire October 14, 2020